SouthBridge Advisory was founded with a simple mission: to bridge the gap between scientific innovation and patient access in advanced therapies. We are a boutique consulting firm with deep expertise in cell & gene therapies and biologics, combining global experience with an unmatched focus on emerging markets. Our leadership team has personally driven some of the most significant milestones in advanced therapy commercialization, including the launch of India’s first international CGT and the scaling of multi-million dollar biologics portfolios across the Emerging Markets.
We understand that emerging markets are where the greatest patient needs exist — and also where the biggest access and affordability barriers remain. That is why SouthBridge was created: to design and execute strategies that bring advanced therapies to patients who would otherwise be left behind. By combining real-world insights, cross-functional expertise, and hands-on execution, we help biopharma companies transform science into sustainable commercial success and meaningful patient impact.
To be the trusted partner for biopharma companies in the Emerging Markets. We aspire to transform advanced therapies into accessible, market-ready solutions.
To bridge science and patient access by delivering pragmatic, execution-focused strategies. We enable breakthrough therapies to reach patients faster and more sustainably.
With over 25 years of experience in advanced therapies, SouthBridge helps companies navigate one of the most complex challenges in healthcare. Whether it’s market entry, pricing design, or commercial execution, we provide clarity, direction, and leadership.
